title: WISP1 polymorphisms contribute to platinum-based chemotherapy toxicity in lung cancer patients.
abstract: Platinum-based chemotherapy toxicity is always one of the serious problems from which lung cancer patients suffer. The genetic polymorphism of WISP1 was revealed to be associated with susceptibility and platinum-based chemotherapy response in our previous studies. In this study, we aimed to investigate the relationship of WISP1 genetic polymorphisms with platinum-based chemotherapy toxicity in lung cancer patients. A total of 412 lung cancer patients were enrolled in this study, and 28 polymorphisms of the WISP1 gene were genotyped by SequenomMassARRAY. We found that WISP1 polymorphisms (rs2929965, rs2929969, rs2929970, rs2929973 and rs754958) were related to the overall chemotherapy toxicity of lung cancer in subgroup analyses. Rs16904853, rs2929970, rs2977549 and rs2977551 (p = 0.021, 0.028, 0.024, 0.048, respectively) polymorphisms were significantly associated with hematologic toxicity. Rs2929946, rs2929970, rs2977519, rs2977536, rs3739262 and rs754958 (p = 0.031, 0.046, 0.029, 0.016, 0.042, 0.035, respectively) polymorphisms were significantly associated with the gastrointestinal toxicity of lung cancer. Genotypes of WISP1 may be novel and useful biomarkers for predicting platinum-based chemotherapy toxicity in lung cancer patients.
authors.affiliation: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China. cj1028@csu.edu.cn.
authors.forename: Juan
authors.initials: J
authors.lastname: Chen
authors.affiliation: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China. yinjiye2005@sina.com.
authors.forename: Jiye
authors.initials: J
authors.lastname: Yin
authors.affiliation: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China. xylxping@126.com.
authors.forename: Xiangping
authors.initials: X
authors.lastname: Li
authors.affiliation: The Affiliated Cancer Hospital of XiangYa School of Medicine, Central South University, Changsha 410014, China. wy552@hotmail.com.
authors.forename: Ying
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China. lizhi1990312@163.com.
authors.forename: Yi
authors.initials: Y
authors.lastname: Zheng
authors.affiliation: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China. qianchenyue0824@foxmail.com.
authors.forename: Chenyue
authors.initials: C
authors.lastname: Qian
authors.affiliation: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China. xiaolingcsu@csu.edu.cn.
authors.forename: Ling
authors.initials: L
authors.lastname: Xiao
authors.affiliation: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China. blingbreeze@163.com.
authors.forename: Ting
authors.initials: T
authors.lastname: Zou
authors.affiliation: Department of Oncology, Xiangya Hospital, Central South University, Changsha 410008, China. wan0916wan@163.com.
authors.forename: Zhan
authors.initials: Z
authors.lastname: Wang
authors.affiliation: Xiangya School of Medicine, Central South University, Changsha 410008, China. liujunyana@126.com.
authors.forename: Junyan
authors.initials: J
authors.lastname: Liu
authors.affiliation: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China. yjsd2003@163.com.
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.affiliation: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China. HHzhou2003@163.com.
authors.forename: Honghao
authors.initials: H
authors.lastname: Zhou
authors.affiliation: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China. liuzhaoqian63@126.com.
authors.forename: Zhaoqian
authors.initials: Z
authors.lastname: Liu
mesh_terms: D000970:Antineoplastic Agents / Q000633:toxicity*; D055511:CCN Intercellular Signaling Proteins / Q000235:genetics*; D005260:Female; D006801:Humans; D008168:Lung / Q000187:drug effects / Q000378:metabolism; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D010984:Platinum / Q000633:toxicity*; D020641:Polymorphism, Single Nucleotide; D011518:Proto-Oncogene Proteins / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D055511:CCN Intercellular Signaling Proteins; C116396:CCN4 protein, human; D011518:Proto-Oncogene Proteins; D010984:Platinum